Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (81-90 of 508) with videos related to

Pageof 51
Sort By:
Lancet (London, England)|August 31, 2010
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialMichael Böhm, Karl Swedberg, Michel Komajda, et al.
Journal of the American Heart Association|February 14, 2016
Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) TrialMichael Böhm, Michele Robertson, Jeffrey Borer, et al.
European Heart Journal|July 11, 2013
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage studyAlex McConnachie, Andrew Walker, Michele Robertson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 19, 2004
Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart diseaseGordon D O Lowe, Ann Rumley, Alex D McMahon, et al.
Advances in Therapy|February 11, 2016
Nicorandil, Gastrointestinal Adverse Drug Reactions and Ulcerations: A Systematic ReviewUmberto Pisano, Jordanna Deosaran, Stephen J Leslie, et al.
Clinical Trials (London, England)|May 10, 2019
There is still a place for significance testing in clinical trialsJonathan A Cook, Dean A Fergusson, Ian Ford, et al.
European Journal of Heart Failure|June 26, 2014
Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFTMichel Komajda, Michael Böhm, Jeffrey S Borer, et al.
Plos One|April 28, 2015
Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY RegistryLaurent Fauchier, Nicola Greenlaw, Roberto Ferrari, et al.
European Heart Journal|April 17, 2010
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-upDavid Preiss, Paul Welsh, Heather M Murray, et al.
Clinical Cardiology|June 1, 2017
Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery diseaseEmmanuel Sorbets, Nicola Greenlaw, Roberto Ferrari, et al.
Pageof 51

Showing results (81-90 of 508) with videos related to

Sort By:
Pageof 51
Lancet (London, England)|August 31, 2010
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialMichael Böhm, Karl Swedberg, Michel Komajda, et al.
Journal of the American Heart Association|February 14, 2016
Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) TrialMichael Böhm, Michele Robertson, Jeffrey Borer, et al.
European Heart Journal|July 11, 2013
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage studyAlex McConnachie, Andrew Walker, Michele Robertson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 19, 2004
Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart diseaseGordon D O Lowe, Ann Rumley, Alex D McMahon, et al.
Advances in Therapy|February 11, 2016
Nicorandil, Gastrointestinal Adverse Drug Reactions and Ulcerations: A Systematic ReviewUmberto Pisano, Jordanna Deosaran, Stephen J Leslie, et al.
Clinical Trials (London, England)|May 10, 2019
There is still a place for significance testing in clinical trialsJonathan A Cook, Dean A Fergusson, Ian Ford, et al.
European Journal of Heart Failure|June 26, 2014
Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFTMichel Komajda, Michael Böhm, Jeffrey S Borer, et al.
Plos One|April 28, 2015
Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY RegistryLaurent Fauchier, Nicola Greenlaw, Roberto Ferrari, et al.
European Heart Journal|April 17, 2010
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-upDavid Preiss, Paul Welsh, Heather M Murray, et al.
Clinical Cardiology|June 1, 2017
Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery diseaseEmmanuel Sorbets, Nicola Greenlaw, Roberto Ferrari, et al.
Pageof 51